ARCA biopharma, Inc (ABIO)

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s Pr

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob Ma-Weaver, the managing member of ARCA’s largest shareholder, to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input as we explore and evaluate strategic options for maximizing stockholder value.” Mr. Ma-Weaver is the Managing Member of Cab

Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value ...

AURORA, CO / ACCESSWIRE / May 17, 2022 / CPC Clinical Research, an academic research organization recognized for its expertise in comprehensive clinical trial design and management, announced that Dr. Connie Hess presented results from the ASPEN-COVID-19 clinical trial at the American Heart Association Vascular Discovery Scientific Sessions held May 12-14, 2022 in Seattle, Washington. Dr. Hess received the American Heart Association 2022 Paul Dudley White International Scholar Award, which is presented to the primary author of the highest ranked abstract submitted from each country to the conference. The clinical trial was conducted on behalf of ARCA biopharma, Inc. (NASDAQ:ABIO).

WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 2022, the Board of Directors established a Special Committee to explore and evaluate strategic options for maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s Pres

Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands ...

WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that its Board of Directors has established a Special Committee to evaluate strategic options for maximizing stockholder value. The Company believes there are multiple potential opportunities to enhance value for ARCA stockholders. The Special Committ

Press release Paris La Défense, 5 April 2022 Governance changes Marie-Claire Daveu has informed Albioma today of her intention to resign from the Board of Directors with effect from 31 July 2022, with her appointment as Director to be submitted to Engie's General Meeting of Shareholders shortly. The composition of the Board of Directors of Albioma will be reviewed accordingly in the coming months. Frédéric Moyne, Chairman and CEO of Albioma, said: “I would like to join all the directors in thank

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you're looking for the biggest pre-market stock movers for Monday, we've got you covered with a list of gainers and losers for today. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Get in Now on Tiny $3 ‘Forever Battery’ Stock It doesn’t matter if you have $500 in savings or $5 million. Do this now. Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Gainers SPI Energy Co., Ltd. (NASDAQ: SPI) rose 36.3% to $3.87 in pre-market trading after reporting record revenue of $162 ...

Gainers Manning & Napier, Inc. (NYSE: MN) jumped 40.7% to $12.82 after the company reported it will be acquired by Callodine ...

U.S. stocks opened higher this morning following the release of non-farm payroll data for March. The Dow traded up 0.17% to 34,735.64 ...

Gainers Yumanity Therapeutics (NASDAQ:YMTX) shares rose 13.3% to $1.7 during Friday's pre-market session. The market ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Reata Completes Regulatory ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! It's the last trading day of the week and that means it's time to get into the pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Get in Now on Tiny $3 ‘Forever Battery’ Stock It doesn’t matter if you have $500 in savings or $5 million. Do this now. Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

ARCA biopharma Inc(NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor ...

Gainers Blackboxstocks Inc. (NASDAQ: BLBX) rose 37.6% to $3.69 in pre-market trading after the company reported ...

Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. For the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reduction compared to baseline in D-dimer levels of 16.8% versus 11.2% for standard of care heparin which was not statistically significant and consequently did not achieve the study primary endpointThe treatment effects of rNAPc2 and heparin were different in Mild versus Severe categories of an adapted WHO

Topline data from Phase 2b ASPEN-COVID-19 clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the last week of March 2022WESTMINSTER, Colo., March 14, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2021 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and

HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Battalion Oil Corporation (NYSE American: BATL, “Battalion” or the “Company”) today announced financial and operating results for the fourth quarter and full year 2021. Key Highlights Reported average daily production of 17,283 Boepd and 16,241 Boepd in fourth quarter and full year 2021, respectivelyProved reserves of 95.9 MMBoe, a 51% increase over year-end 2020 reservesCompleted strategic refinancing in November 2021; enhanced liquidity profile allow

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF)In a Phase 2B clinical trial, the prevalence of clinically important bradycardia was statistically significantly lower for GencaroTM compared to metoprolol WESTMINSTER, Colo., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision med

ARCA biopharma Inc(NASDAQ: ABIO)has completed enrollmentof 160 patients in ASPEN-COVID-19 Phase 2b trial evaluating ...

Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Topline readout of clinical trial results anticipated in first quarter of 2022 WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiovascular diseases, today announced that enrollment has been completed in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potenti

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors ...